Elevidys’ Age-Restricted Indication Not Negotiable, CBER’s Peter Marks Told Sarepta

 
• By Sue Sutter
  
Drug Review Profile: Elevidys
CBER Director Peter Marks told Sarepta his decision on an age-limited indication was not up for negotiation. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Drug Review Profiles

More from Product Reviews